Xvivo Perfusion AB (publ)
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XVIPF research report →
About the company
Xvivo Perfusion AB (publ) is a medical technology company dedicated to advancing transplantation medicine. The firm specializes in pioneering solutions for the preservation and perfusion of organs, tissues, and cells, essential for successful transplant procedures. With a significant international presence, Xvivo Perfusion operates across diverse markets, including Sweden, the United States, wider North and South America, Europe, the Middle East, Africa, and the Asia Pacific region.
- CEO
- Christoffer Rosenblad
- IPO
- 2014
- Employees
- 193
- HQ
- Gothenburg, SE
Price Chart
- Market Cap
- $913.52M
- P/E
- 119.66
- P/S
- 10.57
- P/B
- 4.07
- EV/EBITDA
- 56.09
- Div Yield
- 0.00%
- Gross Margin
- 65.21%
- Op Margin
- 11.79%
- Net Margin
- 8.85%
- ROE
- 3.49%
- ROIC
- 3.28%
- Revenue
- $810.13M · -1.49%
- Net Income
- $25.10M · -85.42%
- EPS
- $0.80 · -85.37%
- Op Income
- $92.78M
- FCF YoY
- -474.37%
- 52W High
- $30.95
- 52W Low
- $16.98
- 50D MA
- $27.04
- 200D MA
- $21.94
- Beta
- 1.46
- Avg Volume
- 5
Get TickerSpark's AI analysis on XVIPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our XVIPF coverage
Recent articles, reports, and earnings notes.
No research on XVIPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XVIPF report →Similar companies
Peers in the same neighborhood.